Literature DB >> 27315223

Suppression of MTHFD2 in MCF-7 Breast Cancer Cells Increases Glycolysis, Dependency on Exogenous Glycine, and Sensitivity to Folate Depletion.

Costas Koufaris1,2, Suchira Gallage1, Tianlai Yang1, Chung-Ho Lau1, Gabriel N Valbuena1, Hector C Keun1.   

Abstract

Methylenetetrahydrofolate dehydrogenase (NAD(P)+ dependent) 2, methenyltetrahydrofolate cyclohydrolase (MTHFD2) is a mitochondrial enzyme involved in folate metabolism. A number of recent studies have highlighted this enzyme as being highly expressed in many solid tumors, including breast cancer, and to be correlated with poor survival. However, the metabolic functions of MTHFD2 in cancer cells have not been well-defined. To investigate the function of MTHFD2 in breast cancer cells, we generated and characterized MCF-7 cells with stable suppression of MTHFD2 expression using a combination of cellular assays and metabolic profiling. Loss of MTHFD2 caused MCF7 cells to become glycine auxotrophs, that is, reliant on exogenous glycine, and more sensitive to exogenous folate depletion. Another prominent metabolic alteration observed as a consequence of MTHFD2 suppression was a more glycolytic phenotype, consistent with widespread modifications of cellular metabolism. Collectively, these data suggest that targeting MTHFD2 activity is likely to influence multiple metabolic pathways in breast cancer and could be combined with a range of antimetabolite therapies.

Entities:  

Keywords:  MCF-7; MTHFD2; cancer; folate; glycine; glycolysis; metabolomics; shRNA

Mesh:

Substances:

Year:  2016        PMID: 27315223     DOI: 10.1021/acs.jproteome.6b00188

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  15 in total

1.  Detection and characterisation of novel alternative splicing variants of the mitochondrial folate enzyme MTHFD2.

Authors:  Vicky Nicolaidou; Christos Papaneophytou; Costas Koufaris
Journal:  Mol Biol Rep       Date:  2020-09-03       Impact factor: 2.316

2.  MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function.

Authors:  Ayaka Sugiura; Gabriela Andrejeva; Kelsey Voss; Darren R Heintzman; Xincheng Xu; Matthew Z Madden; Xiang Ye; Katherine L Beier; Nowrin U Chowdhury; Melissa M Wolf; Arissa C Young; Dalton L Greenwood; Allison E Sewell; Shailesh K Shahi; Samantha N Freedman; Alanna M Cameron; Patrik Foerch; Tim Bourne; Juan C Garcia-Canaveras; John Karijolich; Dawn C Newcomb; Ashutosh K Mangalam; Joshua D Rabinowitz; Jeffrey C Rathmell
Journal:  Immunity       Date:  2021-11-11       Impact factor: 31.745

3.  MTHFD2 facilitates breast cancer cell proliferation via the AKT signaling pathway.

Authors:  Jun Huang; Yinyin Qin; Canfeng Lin; Xiaoguang Huang; Feiran Zhang
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

4.  Serine one-carbon catabolism with formate overflow.

Authors:  Johannes Meiser; Sergey Tumanov; Oliver Maddocks; Christiaan Fred Labuschagne; Dimitris Athineos; Niels Van Den Broek; Gillian M Mackay; Eyal Gottlieb; Karen Blyth; Karen Vousden; Jurre J Kamphorst; Alexei Vazquez
Journal:  Sci Adv       Date:  2016-10-28       Impact factor: 14.136

5.  Human mitochondrial MTHFD2 is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase.

Authors:  Minhye Shin; Jessica Momb; Dean R Appling
Journal:  Cancer Metab       Date:  2017-12-06

6.  Protein interaction and functional data indicate MTHFD2 involvement in RNA processing and translation.

Authors:  Costas Koufaris; Roland Nilsson
Journal:  Cancer Metab       Date:  2018-09-27

Review 7.  Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer.

Authors:  Aamod S Dekhne; Zhanjun Hou; Aleem Gangjee; Larry H Matherly
Journal:  Mol Cancer Ther       Date:  2020-09-02       Impact factor: 6.261

8.  Increased formate overflow is a hallmark of oxidative cancer.

Authors:  Johannes Meiser; Anne Schuster; Matthias Pietzke; Johan Vande Voorde; Dimitris Athineos; Kristell Oizel; Guillermo Burgos-Barragan; Niek Wit; Sandeep Dhayade; Jennifer P Morton; Emmanuel Dornier; David Sumpton; Gillian M Mackay; Karen Blyth; Ketan J Patel; Simone P Niclou; Alexei Vazquez
Journal:  Nat Commun       Date:  2018-04-10       Impact factor: 14.919

Review 9.  More Than a Metabolic Enzyme: MTHFD2 as a Novel Target for Anticancer Therapy?

Authors:  Zhiyuan Zhu; Gilberto Ka Kit Leung
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

10.  The Prognostic Significance of Immune-Related Metabolic Enzyme MTHFD2 in Head and Neck Squamous Cell Carcinoma.

Authors:  Li Cui; Huan Chen; Xinyuan Zhao
Journal:  Diagnostics (Basel)       Date:  2020-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.